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Carlos Jiménez-Romero© 2017 Wolters Kluwer e219decreases from 2.5% of total body weight in young people
to about 1.6% in the nonagenarian population, and several
morphological changes with aging indicate that the liver
cells in advanced old age are in a hyperfunctioning state,
possibly trying to compensate for the decline in total cell
number.4 However, it has been suggested that aging has a
limited effect on liver functions but more on its response to
extrahepatic factors,5 disease states or increased metabolic
demands to which elderly people may have an impaired
ability to respond.4
Atheromatosis usually affects the celiac trunk in old do-
nors but, although this happens rarely, when atheroma oc-
curs distally at the level of the right hepatic artery or at the
bifurcation of the gastroduodenal and the common hepatic
artery, the liver graft must be discarded for LT.2
The LT procedure is a scenario in which many donor
risk factors may be involved. Thus, in our previous brief
communication on octogenarian liver donors, we recom-
mended the use of liver grafts with no age limit but in
good preprocurement condition (hemodynamic stability,
low doses of vasopressor drugs), short intensive care unit
stay, good liver function tests, soft liver consistency, absence
of hepatic artery atheromatosis, cold ischemia time less than
9 hours, and macrosteatosis less than 30%.1 From that time,
we have continued applying the same criteria, but in recent
years we have added other conditions such as implantingReceived 30 November 2016. Revision received 24 January 2017.
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Copyright © 2017 Wolters Kluwer Hthe octogenarian livers into recipients without Hepatitis C virus
(HCV) cirrhosis and model for end-stage liver disease scores
lower than 20 who could tolerate well a probable transient
graft dysfunction.2 As we have seen in this short experience,
it is possible that an octogenarian liver graft can reach the
centennial age after transplant while the recipient maintains
a normal liver function and a good quality of life if a good
donor selection is done, and recipients with HCV cirrhosis
or advanced liver disease are excluded, but at present, with
the current introduction of new anti-HCV drugs, we are also
using these older donors in HCV recipients to decrease the
waiting list mortality. However, further investigations are
needed to demonstrate good results using octogenarian liver
donors in HCV recipients.REFERENCES
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Orthotopic Liver Transplantation
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Christian van Delden, MD,2 Emiliano Giostra, MD,3 Isabelle Morard, MD,3 Nicolas Mueller, MD,4
Beat Muellhaupt, MD,5 Piero V. Valli, MD,5 Nasser Semmo, MD,6 Jörg Seebach, MD,7 Yves Chalandon, MD,1
Laurent Kaiser, MD,2 Eddy Roosnek, PhD,1 and Swiss Transplant Cohort Study (STCS)Replication of torque teno virus (TTV), a nonpathogenic,highly prevalent anellovirus, increases considerably
during immunesuppression.1,2 Recently, Schiemann andcoworkers published the inverse association of TTV load with
rejection after kidney transplantation.3We report similar find-
ings in 39 patients (median age, 60 years [range, 1-73 years];The authors declare no funding or conflicts of interest.
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Study after orthotopic liver transplantation (OLT) for liver
disease of viral (33%), toxic (10%), or other (57%) origins.
We measured TTV-DNA levels by real-time polymerase
chain reaction4 at time of transplantation and at 6 and
12 months posttransplant for the 19 patients with available
serum samples. Seventy-four healthy subjects served as con-
trols (HC). TTV-DNAwas detectable (detection limit 25 viral
copies/mL of plasma) in 29 (74%) of 39 patients at trans-
plantation, a prevalence similar to the one observed in con-
trols (51/74, 69%; P = 0.8035; χ2 test). However, median
TTV-DNA levels were significantly higher in OLT recipients
(median, 4.54  103 copies/mL; range, 25-1.2  108)
compared with controls (median, 1.7  102 copies/mL;
range, 25-5.4  104; P = 0.0014, Mann–Whitney U test)
(Figure 1A). As shown previously,1,2 TTV titers in OLT
recipients increased significantly after transplantation (median,
2  106; range, 25-5.4  108 at 6 months; and median,
2.2  105; range, 25-1.7  107 at 12 months) (Figure 1A).FIGURE 1. TTV load kinetics and impact on the frequency of rejection
episodes after OLT. A, TTV-DNA titers in OLT recipients (filled dots)
compared with healthy controls (HC, white dots). Gray filled dots iden-
tify patients analyzed at time of transplantation (M0) exclusively. Black
filled dots identify patients analyzed at time of transplantation (M0)
and 6 (M6) and 12 months (M12) after transplantation. Comparison
was performed using the Mann–Whitney U test, and P values are in-
dicatedwhen significant (P < 0.05). B, One-year biopsy-proven acute
rejection cumulative incidence in patients displaying detectable
(gray line) and undetectable (black line) TTV-DNA at transplantation.
Cumulative incidence of rejection analysis was performed using Gray
test with death without rejection as a competing event.
Copyright © 2017 Wolters KluwerWe further assessed the relationship between TTV-loads at
transplantation with the risk of biopsy-proven acute cellular
graft rejection (Rejection Activity Index score ≥3 or ≥2
with significant necrosis) during the first year after
transplantation. Interestingly, 1-year cumulative incidence
of rejection in OLT recipients with detectable TTV-DNA
plasma levels at transplantation was significantly lower
(21% [95% confidence interval (CI), 8%-37%]) than in
patients with undetectable TTV titers (70% [95% CI,
28%-90%]; P = 0.0042, Gray test; Figure 1B).
To account for factors with potential impact on TTV
replication and rejection such as age, gender, HBV, HCV,
and HIV serostatus, underlying disease, number of immu-
nosuppressive drugs used, hepatic encephalopathy, and
presence of human leukocyte antigen donor-specific anti-
bodies, we performed a multivariate analysis using Fine-
Gray proportional hazard regression for competing events.
This analysis confirmed the reduced 1-year cumulative inci-
dence of rejection in patients with detectable TTV titers at
time of transplantation (HR, 9  10−3 [95% CI, 1  10−3
to 9.2  10−2; P = 0.00008]).
Our results in OLT recipients are in agreement with those
reported by Schiemann et al for kidney transplant recipients
and reinforce the results of De Vlaminck and coworkers
who found that anellovirus levels in heart and lung trans-
plant recipients with acute rejection episodes were lower
than in nonrejecting patients.5 It is tempting to speculate
that a higher immunocompetence in TTV-negative patients
at transplantation could be responsible for the higher inci-
dence of rejection episodes observed during the first year
after transplantation.
Obviously, our study presents several limitations. First, be-
cause serological testing for TTV is currently unavailable, we
cannot exclude that some patients are TTV-negative simply
because they never have been infected. However, we do
believe that the high prevalence of TTV in the population
makes this unlikely. Second, the study remains somewhat in-
complete because the lack of posttransplant serum samples
precluded the analysis of a potential prognostic value of
TTV titers after OLT. Larger prospective studies with more
patients than in our retrospective pilot study are needed to as-
sesswhethermonitoring TTV titers could help identifying pa-
tients at higher risk of acute rejection after OLT.
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1178–1187.LetterSuccessful Transplantation of 2 Discolored
Kidneys Caused by Myoglobin Casts From a Donor
With Rhabdomyolysis
Chuan-bao Chen, MD,1 Jian Zhou, MD, PhD,1 Xiao-ping Wang, MD, PhD,1 Ming Han, MD, PhD,1
Wen-fang Chen, MD, PhD,2 and Xiao-peng Yuan, MD, PhD1Adiscolored/black kidney has 5 major differentialdiagnoses: massive microthrombi and/or severe
cortical necrosis, hemosiderosis, lipofuscin or melanin
pigment deposits, and oculocutaneous albinism. Renal
hemosiderosis is an indicator of severe intravascular
hemolysis.1 Lipofuscin or melanin pigment deposits
can also cause black kidney.2,3 In addition, oculocutaneous
albinism can result in black kidneys due to accumulation of
ceroid-like material in the lysosomes of the kidney.4
Herein, we report 2 black kidneys which resulted from a
donation after cardiac death (DCD) donor with severe
rhabdomyolysis which were successfully transplanted.
An 18-year-old man was severely injured in a motor vehi-
cle accident. His medical history was unremarkable, withoutchronic anemia, oculocutaneous albinism or other related
syndromes. He was hospitalized in the intensive care unit
for 26 days before donation. His initial laboratory results
were as follows: serum creatinine (SCr), 0.6 mg/dL; creatine
phosphokinase (CPK), 433 units/L; and serum myoglobin,
540 μg/L. His peak CPK was 22 408 units/L, peak serum
myoglobin was 119 617 μg/L, and peak SCr 4.4 mg/dL. At
the time of organ procurement, his SCr was 1.3 mg/dL,
CPK was 439 units/L, and serum myoglobin was 353 μg/L.
Urine output for the 24 hours before organ procurement
was 3550 mL, and the terminal urine output was 150 mL/h.
Organs were donated through the procedure of DCD. The
functional warm ischemic time (starts when the systolic blood
pressure has a sustained fall below 50 mmHg and extends up
to the onset of cold in situ perfusion) was 6 minutes. The time
fromoxygen saturation falls below 70% to the onset of cold in
situ perfusion was 15 minutes. After finishing cold in situ per-
fusion, the kidneys looked black (Figure 1A). Based on the
black appearance, other centers turned down the kidneys.
Wedge biopsy was performed on the right kidney, and frozen
section showed normally structured glomeruli and tubules,
mild edema of tubular epithelial cells, and no microthrombosis
in the vessel loop of the glomeruli. The right kidney was
preserved by static cold storage, and the left kidney was
preserved by a LifePort Organ Recovery Systems, the pump
perfusion lasted for 16 hours with terminal flow 141 mL/min
and resistance 0.16 mm of Hg/(mL/min). Based on the
donor’s history, the renal biopsy pathological results, and
the pump characteristics, the 2 kidneys were accepted for
transplantation at our center.ealth, Inc. All rights reserved.
